Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 11/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SNRNP200 | O75643 | 5/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2131882 | 1.00 | MDM2 (0.81) | MDM2ALDH1A1LMNASNRNP200PDK2 | |
| SCHEMBL249928 | 0.89 | MDM2 (0.65) | MDM2ALDH1A1LMNASNRNP200PDK2 | |
| SCHEMBL2129777 | 0.89 | MDM2 (1.00) | MDM2 | |
| SCHEMBL2624247 | 0.89 | MDM2 (1.00) | MDM2 | |
| SCHEMBL2624229 | 0.89 | MDM2 (1.00) | MDM2 | |
| SCHEMBL2624246 | 0.89 | MDM2 (1.00) | MDM2 | |
| SCHEMBL2624245 | 0.84 | MDM2 (0.90) | MDM2 | |
| SCHEMBL2129510 | 0.84 | MDM2 (0.90) | MDM2 | |
| SCHEMBL2624233 | 0.84 | MDM2 (0.90) | MDM2 | |
| SCHEMBL2131033 | 0.84 | MDM2 (0.74) | MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901117-B2 | Small molecule inhibitors of MDM2 and the uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901117-B2 | Small molecule inhibitors of MDM2 and the uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-12-02 | — | — | US | disclosed |
| US-8742121-B2 | Process for the preparation of small molecule inhibitors of MDM2 and intermediates used therein | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-06-03 | — | — | US | disclosed |
| US-8742121-B2 | Process for the preparation of small molecule inhibitors of MDM2 and intermediates used therein | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130030173-A1 | PROCESS FOR THE PREPARATION OF SMALL MOLECULE INHIBITORS OF MDM2 AND INTERMEDIATES USED THEREIN | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-01-31 | — | — | US | disclosed |
| US-20120101092-A1 | SMALL MOLECULE INHIBITORS OF MDM2 AND THE USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-04-26 | — | — | US | disclosed |
| US-8088931-B2 | Small molecule inhibitors of MDM2 and the uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100273799-A1 | SMALL MOLECULE INHIBITORS OF MDM2 AND THE USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-10-28 | — | — | US | disclosed |
| US-7759383-B2 | INHIBITORS OF MURINE DOUBLE MINUTE-2(MDM2) SUCH AS (2'R,3'S,4'R,5'R)6-CHLORO-4'-2,2-DIMETHYL-PROPYL-2'-(2,2-DIMETHYL-PROPYL)-2-OXO-1,2-DIHYDRO-SPIRO[INDOLE-3,3'-PYRROLIDINE]-5'-CARBOXYLIC ACID(3-MORPHOLIN-4-YL-PROPYL)-AMIDE, USED FOR INDUCING APOPTOSIS AND CELL CYCLE ARREST; ANTIPROLIFERATIVE AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759383-B2 | INHIBITORS OF MURINE DOUBLE MINUTE-2(MDM2) SUCH AS (2'R,3'S,4'R,5'R)6-CHLORO-4'-2,2-DIMETHYL-PROPYL-2'-(2,2-DIMETHYL-PROPYL)-2-OXO-1,2-DIHYDRO-SPIRO[INDOLE-3,3'-PYRROLIDINE]-5'-CARBOXYLIC ACID(3-MORPHOLIN-4-YL-PROPYL)-AMIDE, USED FOR INDUCING APOPTOSIS AND CELL CYCLE ARREST; ANTIPROLIFERATIVE AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273799-A1 | SMALL MOLECULE INHIBITORS OF MDM2 AND THE USES THEREOF | TP53, MDM2, CDKN1A | MDM2 2/4885ALDH1A1 3404/4885LMNA 2439/4885 |
| US-20130030173-A1 | PROCESS FOR THE PREPARATION OF SMALL MOLECULE INHIBITORS OF MDM2 AND INTERMEDIATES USED THEREIN | TP53, MDM2, CDKN1A | MDM2 2/4885ALDH1A1 2896/4885LMNA 1379/4885 |
| US-20120101092-A1 | SMALL MOLECULE INHIBITORS OF MDM2 AND THE USES THEREOF | TP53, MDM2, CDKN1A | MDM2 2/4885ALDH1A1 3404/4885LMNA 2439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.